Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium

Oncology Reports

Volumn 19, Issue 2, 2008, Pages 393-399

  Mukawa, Kenichiroh ^a   Fujii, Shigehiko ^a,b   Tominaga, Keiichi ^a   Yoshitake, Naoto ^a   Abe, Akihito ^a   Kono, Tokuyuki ^a   Sekikawa, Akira ^a   Fukui, Hirokazu ^a   Ichikawa, Kazuhito ^a   Tomita, Shigeki ^a   Imura, Johji ^a   Ono, Yuko ^a   Shinoda, Motoo ^a   Hiraishi, Hideyuki ^a   Fujimori, Takahiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoprevention; Colitis associated tumorigenesis; Cyclooxygenase 2 inhibitor

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DEXTRAN SULFATE; ETODOLAC; PROTEIN P53; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; COLITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPERIMENTAL DESIGN; GASTROINTESTINAL TUMOR; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR MODEL;

EID: 38749129057     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.2.393     Document Type: Article

References (51)

1. Ekbom A, Helmick C, Zack M and Adami HO: Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233, 1990.
2. Gyde SN, Prior P, Allan RN, et al: Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 29: 206-217, 1988.
3. Gilat T, Fireman Z, Grossman A, et al: Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology 94: 870-877, 1988.
4. Riddell RH, Goldman H, Ransohoff DF, et al: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14: 931-968, 1983.
5. Kornbluth A and Sachar DB: Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 99: 1371-1385, 2004.
6. Farrell RJ and Peppercorn MA: Ulcerative colitis. Lancet 359: 331-340, 2002.
7. Lynch DA, Lobo AJ, Sobala GM, Dixon MF and Axon AT: Failure of colonoscopic surveillance in ulcerative colitis. Gut 34: 1075-1080, 1993.
8. Choi PM, Nugent FW, Schoetz DJ Jr, Silverman ML and Haggitt RC: Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 105: 418-424, 1993.
9. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB and Wilkinson KH: Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107: 934-944, 1994.
10. Fujii S, Fujimori T, Chiba T and Terano A: Efficacy of surveillance and molecular markers for detection of ulcerative colitis-associated colorectal neoplasia. J Gastroenterol 38: 1117-1125, 2003.
11. Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
12. Sheehan KM, O'Connell F, O'Grady A, et al: The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas. Eur J Gastroenterol Hepatol 16: 619-625, 2004.
13. Reddy BS, Rao CV, Rivenson A and Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493-1497, 1993.
14. Reddy BS, Rao CV and Seibert K: Evaluation of cyclo-oxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56: 4566-4569, 1996.
15. Bansal P and Sonnenberg A: Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 91: 44-48, 1996.
16. Eaden J, Abrams K, Ekbom A, Jackson E and Mayberry J: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 14: 145-153, 2000.
17. Tardieu D, Jaeg JP, Deloly A, Corpet DE, Cadet J and Petit CR: The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis 21: 973-976, 2000.
18. Takeda J, Kitajima K, Fujii S, et al: Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats. Oncol Rep 11: 981-985, 2004.
19. Fujii S, Fujimori T, Kawamata H, et al: Development of colonic neoplasia in p53-deficient mice with experimental colitis induced by dextran sulphate sodium. Gut 53: 710-716, 2004.
20. Tsukada T, Tomooka Y, Takai S, et al: Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8: 3313-3322, 1993.
21. Schlemper RJ, Riddell RH, Kato Y, et al: The Vienna classfication of gastrointestinal epithelial neoplasia. Gut 47: 251-255, 2000.
22. Cooper HS, Murthy S, Kido K, Yoshitake H and Flanigan A: Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 21: 757-768, 2000.
23. Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 87: 803-809, 1996.
24. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998.
25. Cao Y and Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286, 2002.
26. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
27. Fujita T, Matsui M, Takaku K, et al: Size- and invasion-dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res 58: 4823-4826, 1998.
28. Fujita M, Fukui H, Kusaka T, et al: Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas. J Gastroenterol Hepatol 15: 1277-1281, 2000.
29. Zhang H and Sun XF: Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 97: 1037-1041, 2002.
30. Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993.
31. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
32. Reddy BS, Hirose Y, Lubet R, et al: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60: 293-297, 2000.
33. Brown WA, Skinner SA, Malcontenti-Wilson C, Vogiagis D and O'Brien PE: Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase-1 or cyclooxygenase-2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 48: 660-666, 2001.
34. Jacoby RF, Seibert K, Cole CE, Kelloff G and Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60: 5040-5044, 2000.
35. Agoff SN, Brentnall TA, Crispin DA, et al: The role of cyclooxygenase-2 in ulcerative colitis-associated neoplasia. Am J Pathol 157: 737-745, 2000.
36. Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J and Ohkusa T: Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 17: 1078-1083, 2002.
37. Okayasu I, Ohkusa T, Kajiura K, Kanno J and Sakamoto S: Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39: 87-92, 1996.
38. Fujimori T, Satonaka K, Yamamura-Idei Y, Nagasako K and Maeda S: Non-involvement of ras mutations in flat colorectal adenomas and carcinomas. Int J Cancer 57: 51-55, 1994.
39. Fujii S, Fujimori T and Chiba T: Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia. J Exp Clin Cancer Res 22: 107-115, 2003.
40. Jacoby RF, Llor X, Teng BB, Davidson NO and Brasitus TA: Mutations in the K-ras oncogene induced by 1,2-dimethyl-hydrazine in preneoplastic and neoplastic rat colonic mucosa. J Clin Invest 87: 624-630, 1991.
41. Endo T, Ookawa K, Tanaka M, Nakaji S, Tsuchida S and Sugawara K: Differences in carcinogenesis by the length of carcinogen exposure period in rat colon. Dig Dis Sci 46: 109-117, 2001.
42. Evans JM, McMahon AD, Murray FE, McDevitt DG and MacDonald TM: Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 40: 619-622, 1997.
43. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA and Papadakis KA: The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflam Bowel Dis 10: 352-356, 2004.
44. Bonner GF, Walczak M, Kitchen L and Bayona M: Tolerance of nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 95: 1946-1948, 2000.
45. El Miedany Y, Youssef S, Ahmed I and El Gaafary M: The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 101: 311-317, 2006.
46. Kankuri E, Vaali K, Korpela R, Paakkari I, Vapaatalo H and Moilanen E: Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflammation 25: 301-310, 2001.
47. Reuter BK, Asfaha S, Buret A, Sharkey KA and Wallace JL: Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 98: 2076-2085, 1996.
48. Martin AR, Villegas I and Alarcon de la Lastra C: The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. Inflamm Res 54: 145-151, 2005.
49. Motsko SP, Rascati KL, Busti AJ, et al: Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 29: 621-632, 2006.
50. Fujii S, Tominaga K, Kitajima K, et al: Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut 54: 1287-1292, 2005.
51. Tominaga K, Fujii S, Mukawa K, et al: Prediction of colorectal neoplasia by quantitative methylation analysis of estrogen receptor gene in non-neoplastic epithelium from patients with ulcerative colitis. Clin Cancer Res 11: 8880-8885, 2005.